{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+150+mg&page=2",
    "query": {
      "intervention": "Canakinumab 150 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+150+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab+150+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T15:41:00.406Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05467800",
      "title": "Study of Canakinumab in Patients With Myelofibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "ET-MF",
        "Post-polycythemia Vera Related Myelofibrosis",
        "PV-MF"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-08-02",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tampa, Florida • Westwood, Kansas + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05467800"
    },
    {
      "nct_id": "NCT01900600",
      "title": "Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prior Acute Myocardial Infarction",
        "Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)",
        "Reduced Left Ventricle Ejection Fraction (<50%)",
        "Symptoms of Heart Failure (NYHA Class II-III)"
      ],
      "interventions": [
        {
          "name": "Cardiopulmonary exercise test",
          "type": "OTHER"
        },
        {
          "name": "Echocardiogram",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-04",
      "completion_date": "2015-01-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900600"
    },
    {
      "nct_id": "NCT00770601",
      "title": "Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NOMID",
        "CINCA Syndrome"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 7,
      "start_date": "2009-01-26",
      "completion_date": "2011-02-17",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00770601"
    },
    {
      "nct_id": "NCT01068860",
      "title": "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Canakinumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 246,
      "start_date": "2010-02",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2011-09-05",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068860"
    },
    {
      "nct_id": "NCT00886769",
      "title": "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 84,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00886769"
    },
    {
      "nct_id": "NCT04795466",
      "title": "Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 34,
      "start_date": "2021-10-28",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 2,
      "location_summary": "Charlestown, Massachusetts • Stony Brook, New York",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04795466"
    },
    {
      "nct_id": "NCT00889863",
      "title": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis With Active Flare"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 177,
      "start_date": "2009-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-10-16",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889863"
    },
    {
      "nct_id": "NCT01431638",
      "title": "Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gouty Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab 150mg in prefilled syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 397,
      "start_date": "2011-08-25",
      "completion_date": "2013-05-09",
      "has_results": true,
      "last_update_posted_date": "2021-07-19",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 54,
      "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 50 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431638"
    },
    {
      "nct_id": "NCT01470989",
      "title": "β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gouty Arthritis Flares"
      ],
      "interventions": [
        {
          "name": "ACZ885",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone acetonide 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2011-11",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 33,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Norwalk",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01470989"
    },
    {
      "nct_id": "NCT02059291",
      "title": "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Periodic Fevers"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 203,
      "start_date": "2014-06-27",
      "completion_date": "2017-07-04",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-10-01T15:41:00.406Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059291"
    }
  ]
}